Recent advances in the surgical treatment of benign prostatic hyperplasia

Rocco, Bernardo; Albo, Giancarlo; Ferreira, Rafael Coelho; Spinelli, Matteo; Cozzi, Guido; Dell’Orto, P.; Patel, Vipul; Rocco, Francesco

doi:10.1177/1756287211426301

Cited by 31 publications

(19 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LUTS can be secondary to benign prostatic enlargement, but also bladder and prostate cancers, urinary tract infection, overactive bladder, and neurologic pathologies (87). With all of the advances in the surgical treatment of symptomatic BPH (88), the failure to make strides in providing better medical management may be due to an inability to classify the pathophysiological diversity of the disease.…”

Section: Cells Of Origin For Distinct Bph Phenotypesmentioning

confidence: 99%

Targeting phenotypic heterogeneity in benign prostatic hyperplasia

et al. 2017

View full text Add to dashboard Cite

Benign prostatic hyperplasia and associated lower urinary tract symptoms remain difficult to treat medically, resulting in hundreds of thousands of surgeries performed annually in elderly males. New therapies have not improved clinical outcomes since alpha blockers and 5 alpha reductase inhibitors were introduced in the 1990s. An underappreciated confounder to identifying novel targets is pathological heterogeneity. Individual patients display unique phenotypes, composed of distinct cell types. We have yet to develop a cellular or molecular understanding of these unique phenotypes, which has led to failure in developing targeted therapies for personalized medicine. This review covers the strategic experimental approach to unraveling the cellular pathogenesis of discrete BPH phenotypes and discusses how to incorporate these findings into the clinic to improve outcomes.

show abstract

Section: Cells Of Origin For Distinct Bph Phenotypesmentioning

confidence: 99%

Targeting phenotypic heterogeneity in benign prostatic hyperplasia

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, these techniques are also performed for patients with slightly to moderately enlarged prostates. Rocco et al stated that 100 g is regarded as the limit of weight for those minimally invasive procedures 4. European Association of Urology guidelines also show that open prostatectomy is the treatment of choice for large prostatic glands more than 80–100 mL5 in size.…”

Section: Discussionmentioning

confidence: 99%

A giant prostatic hyperplasia treated by open surgery

Ogawa

Manome²,

Yabe³

et al. 2012

IJGM

View full text Add to dashboard Cite

We report a rare case of giant prostatic hyperplasia treated by open surgery. A 70-year-old man was suffering from macrohematuria. Computed tomography revealed a markedly enlarged prostate measuring 580 mL. The serum prostate-specific antigen level was 9.430 ng/mL. Prostatic biopsy showed benign prostatic hyperplasia. We perfomed retropubic open prostatectomy, since macrohematuria continued and he was also suffering from lower urinary tract symptoms. The adenoma was completely enucleated in one piece. The removed specimen was 13 × 11 × 6 cm in size and weighed 475 g. Histological examination also demonstrated prostatic fibromuscular hyperplasia. This is the 15th-heaviest adenoma ever reported in English-language journals. Transurethral surgical techniques or other minimally invasive approaches are performed for patients with small to medium-sized prostates. However, open surgery is recommended for markedly enlarged prostatic hyperplasia.

show abstract

“…Many of these laser systems use combinations of differing wavelengths to achieve their characteristic properties. The following is a summary of the commercially available la-sers used by urologists [1]:…”

Section: Types Of Lasers Used For Boomentioning

confidence: 99%

Current Laser Therapies for the Treatment of Benign Prostatic Hyperplasia

2016

IJSR

View full text Add to dashboard Cite

Abstract:The gold standard for symptomatic relief of bladder outlet obstruction secondary to be-nign prostatic hyperplasia has traditionally been a transurethral resection of the pros-tate (TURP). Over the past decade, however, novel laser technologies that are patient friendly as compared to the con-ventional TURP have been developed. As part of the ongoing quest to minimize complica-tions, shorten hospitalization, improve resection time, and most importantly reduce mortality, laser prostatectomy has continually evolved. Today, there are more varia-tions of laser prostatectomy, each with several differing surgical techniques. Although abundant data are available confirming the safety and feasibility of the various laser systems, future randomized-controlled trials will be necessary to verify which techni-que is superior. In this article, we describe the most common modalities used to perform a laser prostatectomy, mainly, the holmium laser and the potassium-titanyl-phosphate lasers. We also highlight the physical and clinical characteristics of each technology with a review of their efficacy.

show abstract

Recent advances in the surgical treatment of benign prostatic hyperplasia

Cited by 31 publications

References 48 publications

Targeting phenotypic heterogeneity in benign prostatic hyperplasia

Targeting phenotypic heterogeneity in benign prostatic hyperplasia

A giant prostatic hyperplasia treated by open surgery

Current Laser Therapies for the Treatment of Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About